Optimi Health, a Canada-based pharmaceuticals maker specializing in MDMA and psilocybin, raised $15 million by offering 2.4 million shares at $6.25, within the $6 to $8 range. The company offered 0.1 million fewer shares than anticipated. It originally filed to offer 2.1 million shares, before it increased the share offering in March.
At pricing, Optimi Health has a market cap of less than $50 million, so it will be excluded from Renaissance Capital's 2026 IPO stats.
Optimi Health is a licensed Canadian drug manufacturer that produces controlled substances like MDMA and psilocybin. It operates two facilities in British Columbia and holds multiple licenses that allow it to manufacture, import, and distribute these substances within legal limits. Its approvals cover everything from producing active ingredients from plants to handling and supplying psychedelics in regulated quantities. Optimi is also currently listed on the Canadian Securities Exchange (OPTI) and the Frankfurt Stock Exchange (8BN).
The Princeton, Canada-based company will trade on the Nasdaq under the symbol OPTH. Joseph Gunnar acted as sole bookrunner on the deal.
